The present invention relates to a process for the resolution of DL-racemic mixtures of compounds which crystalize in the form of a conglumerate. Both, the D and L-enantiomers are obtained according to the invention in a industrially feasable process by adding chiral enantioselective polymers to the supersaturated solution of the racemat to inhibit crystalization of one enantiomer. Next a DL-racemic mixture of said compound is suspended in about twice the amount of the crystallized enantiomer. Consequently, the opposite enantiomer could be recovered by said suspension by physical separation.
The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.
-
(2008/06/13)
Optical resolution of DL-cysteine
Disclosed is a method of optical resolution of DL-cysteine utilizing optically active mandelic acid. The method facilitates commercial production of optically active cysteine, particularly L-cysteine which is in great demand.
-
(2008/06/13)
More Articles about downstream products of 32443-99-5